Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer by O'Mara, Tracy A et al.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research
T A O’Mara et al. ESR1 locus fine-mapping for
endometrial cancer
22 :5 851–861Comprehensive genetic assessment
of the ESR1 locus identifies a risk
region for endometrial cancerTracy A O’Mara1, Dylan M Glubb1, Jodie N Painter1, Timothy Cheng2, Joe Dennis3,
The Australian National Endometrial Cancer Study Group (ANECS)1, John Attia4,5,
Elizabeth G Holliday4,5, Mark McEvoy5, Rodney J Scott4,6,7,8, Katie Ashton4,7,8,
Tony Proietto9, Geoffrey Otton9, Mitul Shah10, Shahana Ahmed10,
Catherine S Healey10, Maggie Gorman2, Lynn Martin2, National Study of Endometrial
Cancer Genetics Group (NSECG)2, Shirley Hodgson11, Peter A Fasching12,13,
Alexander Hein13, Matthias W Beckmann13, Arif B Ekici14, Per Hall15, Kamila Czene15,
Hatef Darabi15, Jingmei Li15, Matthias Du¨rst16, Ingo Runnebaum16, Peter Hillemanns17,
Thilo Do¨rk18, Diether Lambrechts19,20, Jeroen Depreeuw19,20,21, Daniela Annibali21,
Frederic Amant21, Hui Zhao19,20, Ellen L Goode22, Sean C Dowdy23, Brooke L Fridley24,
Stacey J Winham22, Helga B Salvesen25,26, Tormund S Njølstad25,26, Jone Trovik25,26,
Henrica M J Werner25,26, Emma Tham27, Tao Liu27, Miriam Mints28, RENDOCAS27,28,
Manjeet K Bolla3, Kyriaki Michailidou3, Jonathan P Tyrer10, Qin Wang3,
John L Hopper29, AOCS Group1,30, Julian Peto31, Anthony J Swerdlow32,33,
Barbara Burwinkel34,35, Hermann Brenner36,37,38, Alfons Meindl39,
Hiltrud Brauch38,40,41, Annika Lindblom27, Jenny Chang-Claude35, Fergus J Couch22,42,
GrahamGGiles29,43,44, Vessela N Kristensen45,46,47, Angela Cox48, Paul D P Pharoah10,
Alison M Dunning10, Ian Tomlinson2, Douglas F Easton3,10, Deborah J Thompson3
and Amanda B Spurdle1
1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute,
300 Herston Road, Herston, Brisbane, Queensland 4006, Australia
2Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
3Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge,
Cambridge CB1 8RN, UK
4Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales 2305, Australia
5School of Medicine and Public Health, Centre for Clinical Epidemiology and Biostatistics, University of Newcastle,
Newcastle, New South Wales 2305, Australia
6Hunter Area Pathology Service, John Hunter Hospital, Newcastle, New South Wales 2305, Australia
7Centre for Information Based Medicine, 8School of Biomedical Sciences and Pharmacy, and 9School of Medicine
and Public Health, University of Newcastle, Newcastle, New South Wales 2308, Australia
10Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge,
Cambridge CB1 8RN, UK
11Department of Clinical Genetics, St George’s, University of London, London SW17 0RE, UK
12Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine,
University of California at Los Angeles, Los Angeles, California 90095, USA
13Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University
Erlangen-Nuremberg, Erlangen 91054, Germany
14Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg,
Erlangen 91054, Germany
15Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-171 77, Sweden
16Department of Gynaecology, Jena University Hospital – Friedrich Schiller University, Jena 07743, Germany
17Hannover Medical School, Clinics of Gynaecology and Obstetrics, Hannover 30625, Germany
18Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany
19Vesalius Research Center, Leuven 3000, Belgium
20Laboratory for Translational Genetics, Department of Oncology, University Hospitals Leuven,
Leuven 3000, Belgiumhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great Britain
Published by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research T A O’Mara et al. ESR1 locus fine-mapping for
endometrial cancer
22 :5 85221Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals,
KU Leuven – University of Leuven, 3000, Belgium
22Department of Health Sciences Research, and 23Division of Gynecologic Oncology, Department of Obstetrics and
Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
24Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
25Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen 5020, Norway
26Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen 5021, Norway
27Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-171 77, Sweden
28Department of Women’s and Children’s Health, Karolinska Institutet, Karolinska University Hospital,
Stockholm SE-171 77, Sweden
29Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics,
The University of Melbourne, Melbourne, Victoria 3010, Australia
30Peter MacCallum Cancer Center, The University of Melbourne, Melbourne 3002, Australia
31London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
32Division of Genetics and Epidemiology, Institute of Cancer Research, London SM2 5NG, UK
33Division of Breast Cancer Research, Institute of Cancer Research, London SM2 5NG, UK
34Department of Gynecology and Obstetrics, Molecular Biology of Breast Cancer, University of Heidelberg,
Heidelberg 69120, Germany
35Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
36Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ),
Heidelberg 69120, Germany
37Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
38German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
39Division of Tumor Genetics, Department of Obstetrics and Gynecology, Technical University of Munich,
Munich 0333, Germany
40Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany
41University of Tu¨bingen, Tu¨bingen 72074, Germany
42Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
43Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia
44Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
45Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo 0310, Norway
46The KG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine,
University of Oslo, Oslo 0316, Norway
47Department of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital,
Lørenskog 1478, Norway
48Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield S10 2RX, UKhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great Britain
Published by Bioscientifica Ltd.Correspondence
should be addressed
to A B Spurdle
Email
Amanda.Spurdle@
qimrberghofer.edu.auAbstractExcessive exposure to estrogen is a well-established risk factor for endometrial cancer (EC),
particularly for cancers of endometrioid histology. The physiological function of estrogen is
primarily mediated by estrogen receptor alpha, encoded by ESR1. Consequently, several
studies have investigated whether variation at the ESR1 locus is associated with risk of EC,
with conflicting results. We performed comprehensive fine-mapping analyses of 3633
genotyped and imputed single nucleotide polymorphisms (SNPs) in 6607 EC cases and
37 925 controls. There was evidence of an EC risk signal located at a potential alternative
promoter of the ESR1 gene (lead SNP rs79575945, PZ1.86!10K5), which was stronger for
cancers of endometrioid subtype (PZ3.76!10K6). Bioinformatic analysis suggests that this
risk signal is in a functionally important region targeting ESR1, and eQTL analysis found that
rs79575945 was associated with expression of SYNE1, a neighbouring gene. In summary, we
have identified a single EC risk signal located at ESR1, at study-wide significance. Given SNPs
located at this locus have been associated with risk for breast cancer, also a hormonally
driven cancer, this study adds weight to the rationale for performing informed candidate
fine-scale genetic studies across cancer types.Key Words
" endometrial cancer
" ESR1
" single-nucleotide
polymorphisms
" fine-mapping analysisEndocrine-Related Cancer
(2015) 22, 851–861
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22 :5 853IntroductionEndometrial cancer is the most commonly diagnosed
gynaecological malignancy in developed countries
(http://globocan.iarc.fr/). Excessive endogenous and
exogenous estrogen exposure or estrogen exposure unop-
posed by progesterone is a well-established risk factor for
the development and progression of endometrial cancer
(Kaaks et al. 2002,Key&Pike1988). Estrogen receptor alpha
(encoded by ESR1) is the predominant receptor responsible
for mediating the effects of estrogen in the endometrium.
A number of studies have previously been performed
to investigate the hypothesis that variation at the ESR1
locus may be associated with predisposition to endo-
metrial cancer (Weiderpass et al. 2000, Sasaki et al. 2002,
Iwamoto et al. 2003, Einarsdottir et al. 2008, 2009,Wedren
et al. 2008, Ashton et al. 2009, 2010, Sliwinski et al. 2010,
Li et al. 2011), but results from these relatively under-
powered studies (maximum sample size 713 cases and
1567 controls) have been conflicting. However, compre-
hensive candidate gene and genome-wide association
studies of breast cancer, which shares many risk factors
with endometrial cancer, have identified cancer-associ-
ated risk variants at the ESR1 locus (Dunning et al. 2009,
Zheng et al. 2009, Turnbull et al. 2010, Hein et al. 2012).
These findings indicate a need for similar large-scale and
comprehensive genetic analysis of endometrial cancer
to elucidate the role of ESR1 variants in the risk of
endometrial cancer.
Here we present the results from fine-mapping of the
ESR1 locus by dense SNP genotyping and imputation in
6607 endometrial cancer cases and 37 925 controls of
European descent within the Endometrial Cancer
Association Consortium.Materials and methods
Datasets
Genotyping of the fine-mapping dataset was performed
on a custom Illumina Infinium iSelect array (‘iCOGS’;
designed by the Collaborative Oncological Gene-environ-
ment Study, details summarized in Bahcall (2013)). All
studies have the relevant IRB approval in each country in
accordance with the principles embodied in the Declara-
tion of Helsinki, and informed consent was obtained from
all participants. Details of iCOGS genotyping of endo-
metrial cancer cases and control samples can be found in
Supplementary Table 1, see section on supplementary data
given at the end of this article and in Painter et al. (2014).http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainAll cases and controls selected for analysis were of
European ancestry, as defined by Identity-By-State (IBS)
scores between study individuals and individuals in
HapMap (http://hapmap.ncbi.nlm.nih.gov/). The final
analysis of the iCOGS dataset included genotypes for
4401 women with a confirmed diagnosis of endometrial
cancer and 28 758 healthy female controls genotyped
by the Breast Cancer Association Consortium (BCAC) or
the Ovarian Cancer Association Consortium (OCAC).
Additionally, three Caucasian GWAS datasets (ANECS,
SEARCH and NSECG) were as previously described,
totalling 2206 cases and 9167 controls after quality control
(Spurdle et al. 2011, Painter et al. 2014). Overall, there were
6607 endometrial cancer cases and 37 925 controls
included in the meta-analysis of the four datasets
(ANECS, SEARCH and NSECG GWAS datasets and the
iCOGS dataset).Fine-mapping
The study herein includes SNPs in a 1 Mb region including
ESR1 (chr6: 151 600 000–152 650 000; NCBI build 37
assembly). SNPs with a minor allele frequency O2% using
the1000GenomesProject (March2010Pilot version60CEU
project data) were considered for inclusion for ESR1 fine-
mapping on the iCOGS array by BCAC. In total, 975 SNPs
were selected, comprising277 SNPs correlated (r2O0.1)with
three previously reported breast cancer associated SNPs
(rs2046210, rs3757318 and rs3020314), and a 698 SNP set
tagging all remaining SNPs in the region with r2O0.9.Regional imputation
Genotypes for SNPs present in 1000 Genomes Phase 1
(April 2012 release) were imputed for the fine-mapping
dataset and each GWAS dataset using IMPUTE V2.0
(Howie et al. 2009). Imputation was performed separately
for each dataset. SNPs with an imputation information
scoreO0.8 for all four datasets and minor allele frequency
O0.01 were included in analysis. Following quality
control, a total of 3633 genotyped and imputed SNPs
were available across all four datasets (the three GWAS and
iCOGS datasets).Association analysis
Odds ratios for each SNP were estimated for the four
imputed datasets separately, using unconditional logisticPublished by Bioscientifica Ltd.
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22 :5 854regression with a per-allele (one degree-of-freedom)
model, based on the expected genotyped dosages for the
imputed SNPs. The GWAS datasets were each analysed as a
single stratum, with adjustment for the first two (ANECS
and NSECG) and three (SEARCH) principal components.
For the iCOGS dataset, analyses were performed adjusting
for strata and for the first ten principal components, as
previously described (Painter et al. 2014). The numbers of
principal components included in the analyses were
selected to adequately account for population stratifica-
tion in each of the datasets. Results from the four studies
were combined using standard fixed-effects meta-analysis,
and between-study heterogeneity assessed by Q statistic
(Higgins & Thompson 2002). Risk estimation was per-
formed separately for each tested phenotype (endometrial
cancer, endometrioid endometrial cancer, non-endome-
trioid endometrial cancer). To determine independently
associated SNPs, we used forward stepwise logistic
regression based on all SNPs with P!0.05 in the single-
SNP analysis. At each stage, SNPs were included in the
model if they were significant at P!0.05 after adjustment
for other SNPs. To assess possible interaction with
BMI group (%30 kg/m2 or O30 kg/m2) for lead SNP
rs79575945, the significance of multiplicative interaction
was assessed by the change in the likelihood ratio estimate
after inclusion of a BMI-by-genotype interaction term to
a simpler model without this term. Analyses were
conducted using R, including the GenABEL (Aulchenko
et al. 2007), meta packages (Schwarzer 2010) and
SNPTESTv2 (Ferreira & Marchini 2011). All statistical
tests were two-sided.eQTL analysis
Data from endometrial tumours were accessed from The
Cancer Genome Atlas (TCGA) (Cancer Genome Atlas
Research Network et al. 2013). Germline SNP genotypes
(Affymetrix 6.0 arrays) were downloaded through the
controlled access portal, while epidemiological data,
normalized RNA-Seq data and copy-number information
were downloaded through the public access TCGA portal.
There were 290 TCGA patients (221 endometrioid
histology) with complete genotype, RNA-Seq and copy-
number data included in the analysis. Quality control was
performed on the germline SNP genotypes as previously
described (Carvajal-Carmona et al. 2015). To increase the
number of SNPs in the analysis, we imputed genotypes for
SNPs present in the 1000 Genomes dataset v3 in the ESR1
region (chr6: 150 125 000–152 650 000, April 2012 release)
which were not genotyped by the Affymetrix 6.0 platformhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great Britainusing minimac (Howie et al. 2012, Fuchsberger et al. 2015)
Software. Haplotypes were phased using the MaCH
program (Li et al. 2009, 2010) before running minimac
for genotype imputation, using the recommended para-
meters (20 iterations of the Markov sampler and 200
states). SNPs imputed with a RSQR (quality measure)O0.8
and minor allele frequency O0.01 were included in the
eQTL analysis. RNA-Seq expression for genes 500 kb
upstream and downstream of ESR1 (SYNE1, ESR1,
CCDC170, C6orf211, RMND1, ZBTB2, AKAP12, MYCT1)
were adjusted for somatic copy number variation, as
previously described by Li et al. (2013). The associations
between genotype and adjusted expression for each gene
were evaluated using linear regression models by the
mach2qtl program (Li et al. 2009,2010). Associations were
considered to be statistically significant after correction for
the total number of genes analysed across the region
(0.05/8 genesZ6.25!10K3).Results
Meta-analysis performed on 3633 SNPs that passed quality
control criteria in the four studies (iCOGS, ANECS,
SEARCH and NSECG) identified 401 SNPs associated
with endometrial cancer risk with P!0.05 (Supplementary
Table 2, see section on supplementary data given at the
end of this article), compared to 182 expected by chance.
When analysis was restricted to endometrioid-only endo-
metrial cancer, 411 mostly overlapping SNPs were
identified to be associated with a P!0.05 (Supplementary
Table 2).
Imputed SNP rs79575945 displayed the strongest
association for endometrial cancer risk (per A-allele OR
0.85 and 95% CI 0.79–0.92, PZ1.85!10K5; Fig. 1). The risk
association was slightly stronger for endometrioid endo-
metrial cancer (per A-allele OR 0.83 and 95% CI 0.77–0.90,
PZ3.76!10K6; 5611 endometrioid cases and 37 926 con-
trols). No other SNPs reached significance (P!1.85!10K5)
after conditioning on rs79575945, suggesting the presence
of a single endometrial risk signal at this locus. Similar
associations were observed for rs9341019 in the same
linkage disequilibrium (LD) block as rs79575945, which
was genotyped in all four datasets (rs9341019 OR 0.84 and
95% CI 0.76–0.92, PZ2.2!10K4; r2Z0.27 to rs79575945).
Supplementary Table 3, see section on supplementary
data given at the end of this article lists the 47 SNPs most
likely to be the causal variant underlying the risk
associations with most significant ‘lead’ SNPs
rs79575945. This SNP set was defined as the SNPs which
were in LD (r2O0.2) and had a likelihood of associationPublished by Bioscientifica Ltd.
Study Odds ratio OR 95% CI
All histologies
SEARCH GWAS
ANECS GWAS
NSECG GWAS
iCOGS
Fixed effect model
Endometrioid histology
SEARCH GWAS
ANECS GWAS
NSECG GWAS
iCOGS
Fixed effect model
Overall: I2=0%, P=0.8975
0.75 1 1.5
P=3.79 × 10–6
P=1.86 × 10–5
0.90
0.83
0.84
0.82
0.83
(0.73; 1.11)
(0.66; 1.05)
(0.65; 1.08)
(0.74; 0.90)
(0.77; 0.90)
0.90
0.83
0.84
0.85
0.85
(0.73; 1.11)
(0.66; 1.05)
(0.66; 1.07)
(0.78; 0.93)
(0.79; 0.92)
Overall: I2=0%, P=0.9675
Figure 1
Forest plot of odds ratios for the GWAS and iCOGS fine-mapping datasets
for SNP rs79575945 for all histologies and for endometrioid histology.
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22 :5 855with endometrial cancer !100:1 with the relevant lead
SNP (Carvajal-Carmona et al. 2015, Glubb et al. 2015).
Given BMI is a major epidemiological risk factor for
endometrial cancer, analyses were repeated adjusting
for BMI in the subset of cases (nZ4088) and controls
(nZ16 590) for whom BMI data were available, and also
assessing the possible interaction of rs79575945 with BMI
group (%30 kg/m2 orO30 kg/m2). Therewas no discernible
difference in effect for rs79575945 (unadjusted ORZ0.86,
PZ2.4!10K3; adjusted ORZ0.82, PZ3.7!10K4), and no
significant evidence of interaction of rs79575945 with BMI
(P-interactionZ0.15).
SNP rs79575945 was not significantly associated with
risk of non-endometrioid endometrial cancer (OR 0.94
and 95% CI 0.80–1.13, PZ0.54), although there was
reduced power to detect association due to the smaller
case sample size (iCOGS fine-mapping and NSECG GWAS
datasets only, case nZ887). No SNP reached study-wide
significance for non-endometrioid endometrial cancer
risk. Similarly, no significant associations were found in
the case-only analysis, comparing endometrioid endo-
metrial cancer patients to non-endometrioid patients
(rs79575945 OR 1.08 and 95% CI 0.89–1.30, PZ0.43).
None of the 47 potentially causal variants (Supple-
mentary Table 3, see section on supplementary data given
at the end of this article) showed evidence of an
association with ESR1 expression, using genotype and
RNA-Seq data from TCGA. The strongest association
observed for any SNP in this region with ESR1 levels in
endometrioid endometrial tumours was rs74575485
located upstream of the rs79575945 risk signal
(r2Z0.001), but this SNP was not associated with riskhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great Britain(eQTL PZ1.45!10K3, risk PZ0.77). We found evidence of
an association between the top risk SNP rs79575945 and
increased expression of SYNE1 in endometrioid endo-
metrial tumour (eQTL PZ3.17!10K3). This association is
considered to be statistically significant after correcting
for the total number of genes analysed across the region
(P for significanceZ6.25!10K3).
We integrated location of candidate causal SNPs with
publicly available genomic data to assess likely functional
relevance of SNPs. Candidate causal SNPs mapped to a
potential regulatory element,whichwedefinedby evidence
of enhancer-specific histone modification (mono-methyl-
ation of H3 lysine 4 (H3K4Me1)), DNaseI hypersensitivity
sites representative of open chromatin, and regions bound
by transcription factors (Fig. 2). Super-enhancers annotated
in the study byHnisz et al. (2013)were also found to overlap
with candidate causal SNPs (Fig. 2), indicating the
functional importanceof this region. Importantly, ENCODE
data showed presence of DNaseI hypersensitivity sites and
evidence for binding of transcription factors in Ishikawa
endometrial cancer cells, indicating these regions may be
active in endometrial tumours. The binding of these
transcription factors were not found to be altered by the
candidate causal SNPs, using two independent in silico
prediction algorithms (Supplementary Table 4, see section
on supplementary data given at the end of this article).
Candidate causal SNP rs9340770 was predicted to alter
binding of p300 by HaploReg, and ENCODE data have
shown p300 binding to occur at this region in Ishikawa cells
(Encode Project Consortium et al. 2012).Discussion
We have performed the largest and most comprehensive
study assessing the association of SNPs across the ESR1
gene with endometrial cancer risk. We provide evidence of
a study-wide significant association between endometrial
cancer risk and imputed SNP rs79575945. Our study
implemented parameters to reduce imputation errors
and minimize false-positive associations, including
rigorous pre-imputation quality control, excluding rare
SNPs (minor allele frequency !0.01) and using a high
imputation quality score threshold (O0.8) for analyses
(Marchini & Howie 2010). These measures, and the similar
association observed for the best genotyped SNP in the
same LD block as imputed lead SNP rs79575945, increase
our confidence for the observed association. Given the
strong prior evidence for association of this region with a
hormonal cancer, as well as with other hormone-related
phenotypes (Estrada et al. 2012, Perry et al. 2014),Published by Bioscientifica Ltd.
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Figure 2
Association results for all SNPs with endometrial cancer risk from the meta-
analysis are shown in the first panel, and association with endometrioid
histological subtype the second panel. There was the same number of
genotyped or well-imputed samples available for the analysis of each SNP.
Only SNPs passing quality control (information scoreO0.8 and minor allele
frequencyO0.01 across all datasets) are plotted as the negative log of the
P value against relative position across the locus (base position (hg19)
displayed across the top). SNPs genotyped in the iCOGS dataset are
displayed as diamonds and SNPs imputed as circles. The lead SNP,
rs79575945, is shown as a green filled circle and LD with surrounding SNPs
indicated by colour (SNPs r2R0.8 are red, r2R0.5 and !0.8 are orange,
r2R0.2 and !0.5 are yellow and r2!0.2 are unfilled). The SNP most
strongly associated with ESR1 expression in endometrial cancer tumours is
shown as a filled blue circle. Red horizontal dashed lines denote study-wide
significance thresholds (PZ2!10K4). The third panel shows a schematic of
gene structures with exons (vertical boxes) joined by introns (lines).
Enhancers predicted in Hnisz et al. (2013) which overlap SNPs associated
with the three phenotypes are depicted as coloured bars, where the colour
matches the schematic of its predicted target gene. Histone modification
associated with promoters (H3K4Me1) from seven ENCODE Project cell
types are indicated. DNaseI hypersensitivity sites (DHS) and transcription
factor (TF) binding identified in 125 and 91 ENCODE Project cell types
respectively, are displayed. DNaseI HS and transcription factor binding
regions in Ishikawa endometrial cancer cells* are also shown. The grey
vertical stripe indicates the putative promoter region overlapping the risk
signal. *Note in 2015 ENCODE re-identified ECC-1 cells as Ishikawa (https://
www.encodeproject.org/biosamples/ENCBS312UTV/) (Korch et al. 2012).
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22 :5 856we considered this a candidate-gene study. The consist-
ency of SNP association with endometrial cancer risk
between the four studies gives us confidence in this
finding. Using tagger (de Bakker et al. 2005), 246 SNPs
were calculated to be required to tag our region of interest
by pairwise-tagging (r2R0.5). Themost strongly associated
SNP had a P value an order of magnitude smaller than
the Bonferroni-adjusted significance threshold based on
the number of independent SNPs at the locus (P for
significanceZ0.05/246Z2.0!10K4). Notably, there was
a more significant association for the endometrioid
histology subtype which is well-established to be estrogen
driven (Kaaks et al. 2002).http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainNeither SNP rs79575945, nor any other in the risk-
associated SNP set, has been previously reported to be
associated with endometrial cancer risk. Reported associ-
ated SNPs from smaller candidate studies investigating the
effect of genetic variation at the ESR1 locus on endometrial
cancer risk are not in LD (r2!0.2) with rs79575945 and
were not validated in our larger study (Table 1).
SNPs associated with multiple phenotypes have been
mapped to the ESR1 locus, notably breast cancer (Zheng
et al. 2009, Turnbull et al. 2010, Hein et al. 2012), which
shares many risk factors with endometrial cancer, and age-
of-menarche (Perry et al. 2014) and bone mineral density
(Estrada et al. 2012), which are both associated withPublished by Bioscientifica Ltd.
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22 :5 858estrogen exposure. However, none of the SNPs reported by
these studies are correlated with any of the variants found
to be associated with endometrial cancer risk (r2!0.2).
The lack of overlap between risk variants for endometrial
cancer, breast cancer and risk factors associated with
estrogen exposure suggest that while these risks could be
mediated through the same target gene, they are working
via different regulatory mechanisms in different cell types.
Using log-likelihood ratios and LD, we have identified
47 candidate causal variants located at a potential
alternative promoter of ESR1, represented by lead SNP
rs79575945. Bioinformatics data provide evidence that
these variants reside within a putative regulatory element
for ESR1 and/or other genes in this region. By cross-
referencing the catalogue created using 86 cell lines by
Hnisz et al. (2013), we also provide evidence that candidate
causal variants lie in a region encompassing super-
enhancers that target ESR1. Super-enhancers consist of
large clusters of transcriptional enhancers and are associ-
atedwith genes that control anddefine cell identity (Loven
et al. 2013, Whyte et al. 2013). The presence of super-
enhancers overlapping the candidate causal variants
indicates the functional importance of this region. Four
candidate causal variants were predicted to alter transcrip-
tion factor binding by two independent programs, is-rSNP
(Macintyre et al. 2010) andHaploReg (Ward& Kellis 2012).
However, none of these transcription factors identified
have been examined by ENCODE. There was evidence of
binding of transcription factors TAF1, NFIC, TCF12, p300,
TEAD4 and FOXM1 overlapping candidate causal SNPs in
Ishikawa cells by ENCODE. However, the binding of these
transcription factors were not found to be altered by the
candidate causal SNPs using is-rSNP and HaploReg. Given
transcription factor binding frequently occurs in the
absence of a known motif (Kheradpour & Kellis 2014),
SNP effects may not have been correctly assessed in this
analysis. Functional analysis would therefore be required
to assess the impact of these SNPs on transcription factor
binding.Usingdata fromHaploReg alone, candidate causal
SNP rs9340770 was predicted to alter binding of p300 and
ENCODEdata indicates that rs9340770 is in a regionbound
by p300 in Ishikawa cells. SNP rs9340770 is located
upstream of an alternative transcript for ESR1, and the
binding of p300 suggests this could be a putative promoter
for these transcripts. Further functional work is required
to uncover whether this SNP is affecting the expression of
these alternative transcripts by disrupting p300 binding.
Although predicted to be the target gene bioinforma-
tically, eQTL analysis using TCGA data did not find the
candidate causal SNPs to be significantly associated withhttp://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainESR1 expression. This is in line with previous fine-
mapping studies performed for breast cancer, where
candidate causal variants have not been found to act as
eQTLs for predicted target genes in breast tissue samples
(Ghoussaini et al. 2014, Glubb et al. 2015). The reason for
this is unclear. It is possible that the effect of candidate
SNPs on expression levels cannot always be detected in
tumour tissue due to tissue-heterogeneity. Furthermore,
eQTLs are context-dependent and might only be
expressed in certain stages of cancer development, or
only when under particular stimuli.
We did find candidate causal SNPs to be significantly
associated with spectrin repeat containing, nuclear envel-
ope 1 (SYNE1) expression in endometrioid endometrial
cancer tissue. SYNE1 encodes Nesprin-1 which is reported
to be involved in a variety of cellular processes, including
Golgi and nucleus organization and cytokinesis (Zhang
et al. 2001, Gough et al. 2003, Fan & Beck 2004). Genetic
variation in SYNE1 has been reported to be associated with
increased risk of invasive ovarian cancer (Doherty et al.
2010). SYNE1 is frequently methylated in lung adeno-
carcinoma and colorectal cancer (Schuebel et al. 2007,
Tessema et al. 2008) and mutations in SYNE1 have been
reported in colorectal cancer (Sjoblom et al. 2006).
Downregulation of an N-terminal isoform of Nesprin-1,
Drop1, has been observed in cancers of the uterus, cervix,
kidney, thyroid, pancreas and lung (Marme et al. 2008).
Interestingly, a recent study has indicated a role for
Nesprin-1 in the DNA damage response pathway, and
identified Nesprin-1 as interacting with mismatch repair
proteins MSH2 and MSH6 (Sur et al. 2014). Given that
mismatch repair deficiency is observed in up to 30% of
endometrial tumours (Kanaya et al. 2003), and the eQTL
data from our study, the role of SYNE1 in endometrial
cancer should be explored further.
In conclusion, we have identified a single endometrial
cancer risk signal, at study-wide significance, located
within a potential alternative promoter for ESR1. Lead
SNP, rs79575945 is also reported to be associated with
expression of SYNE1, adjacent to ESR1. Given SNPs at this
locus have previously been identified as predisposing to
breast cancer, also a hormonally driven cancer, this study
adds weight to the rationale for performing informed
candidate fine-scale genetic studies across cancer types
(Carvajal-Carmona et al. 2015).Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
ERC-15-0319.Published by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research T A O’Mara et al. ESR1 locus fine-mapping for
endometrial cancer
22 :5 859Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This work was supported by the National Health and Medical Research
Council of Australia (ID#1031333 to A B Spurdle, DF, A M Dunning,
ID#39435 to ANECS, ID#552402, QIMR Controls); National Health and
Medical Research Council of Australia Fellowship Scheme (to A B Spurdle);
Principal Research Fellow of Cancer Research UK (to D F Easton); Joseph
Mitchell Trust (to A M Dunning); Oxford Comprehensive Biomedical
Research Centre (to I Tomlinson); The European Community’s Seventh
Framework Programme (grant agreement number 22175 (HEALTH-F2-
2009-223175) (COGS); Cancer Research UK (C1287/A10118 to COGS and
BCAC, C1287/A10710, C12292/A11174, C1281/A12014 to COGS and BCAC,
C5047/A15007, C5047/A10692, C8197/A16565, C490/A10124 to SEARCH,
CORGI - NSECG, to I Tomlinson); National Institutes of Health (CA128978,
R01 CA122443 to MECS and MAY, P30 CA15083 to MECS, P50 CA136393 to
MECS and MAY, CAHRES); Post-Cancer GWAS Initiative (1U19 CA148537,
1U19 CA148065, 1U19 CA148112 – the GAME-ON initiative); Department of
Defence (W81XWH-10-1-0341); Canadian Institutes of Health Research
(CIHR) for the CIHR Team in Familial Risks of Breast Cancer; Komen
Foundation for the Cure; The Breast Cancer Research Foundation; Ovarian
Cancer Research Fund (to COGS); Cancer Council Queensland (ID#4196615
to ANECS); Council Cancer Tasmania (ID#403031, #ID457636 to ANECS);
Medical Research Council (G0000934 to the British 1958 Birth Cohort);
Wellcome Trust (068545/Z/02, 085475 to the British 1958 Birth Cohort);
Wellcome Trust Human Genetics Grant (090532/Z/09/Z to NSECG); European
Union (EU FP7 CHIBCHA to NSECG); The University of Newcastle (to QIMR
Controls, to NECS); Gladys M Brawn Senior Research Fellowship (QIMR
Controls); The Vincent Fairfax Family Foundation (QIMR Controls); Hunter
Medical Research Institute (HCS, NECS); Hunter Area Pathology Service
(HCS); ELAN fund of the University of Erlangen (BECS); Verelst Foundation
for endometrial cancer (LES); Fred C and Katherine B Anderson Foundation
(to MECS, to MAY); Mayo Foundation (to MECS, to MAY); Ovarian Cancer
Research Fund with support of the Smith family, in memory of Kathryn
Sladek Smith (MECS, PPD/RPCI.07 to OCAC); Helse Vest Grant (MoMaTEC);
University of Bergen (MoMaTEC); Melzer Foundation (MoMaTEC); The
Norwegian Cancer Society – Harald Andersens legat (MoMaTEC); The
Research Council of Norway (MoMaTEC); Haukeland University of Hospital
(MoMaTEC); NBN Children’s Cancer Research Group (NECS); Ms Jennie
Thomas (NECS); regional agreement on medical training and clinical
research (ALF) between Stockholm County Council and Karolinska
Institutet (20110222, 20110483, 20110141 and DF 07015 all to RENDOCAS,
to KARBAC); The Swedish Labor Market Insurance (100069 to RENDOCAS);
The Swedish Cancer Society (11 0439 to RENDOCAS); Agency for Science,
Technology and Research of Singapore (CAHRES); Susan G Komen Breast
Cancer Foundation (CAHRES); UK National Institute for Health Research
Biomedical Research Centres at the University of Cambridge (OCAC);
Baden-Wu¨rttemberg state Ministry of Science, Research and Arts (ESTHER);
Federal Ministry of Family Affairs, Senior Citizens, Women and Youth
(ESTHER); Federal Ministry of Education and Research (BMBF) Germany
(01KW9975/5 to GENICA, 01KW9976/8 to GENICA, 01KW9977/0 to GENICA,
01KW0114 to GENICA, to ESTHER); Robert Bosch Foundation (GENICA);
Deutsches Krebsforschungszentrum – DKFZ (GENICA); Institute for Preven-
tion and Occupational Medicine of the German Social Accident Insurance,
Institute of the Ruhr University Bochum, IPA (GENICA); Department of
Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter
Krankenhaus (GENICA); Deutsche Krebshilfe e.V. (70-2892-BR I to MARIE);
Hamburg Cancer Society (MARIE); German Cancer Research Center (MARIE);
Breast Cancer Research Foundation (MCBCS); David F. and Margaret T.
Grohne Family Foundation (MCBCS); Ting Tsung and Wei Fong Chao
Foundation (MCBCS); VicHealth (MCCS); Cancer Council Victoria (MCCS);http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainBreakthrough Breast Cancer (UKBGS); Institute of Cancer Research (UKBGS);
and NHS funding to the NIHR Biomedical Research Centre (UKBGS/ICR).Author contribution statement
A M Dunning, D F Easton, P D P Pharoah, I Tomlinson and A B Spurdle
obtained funding for the study. D F Easton and A B Spurdle designed the
study and A B Spurdle and T A O’Mara drafted the manuscript. T A O’Mara
conducted all statistical analyses. D J Thompson conducted genotype
imputation. D M Glubb and T A O’Mara conducted bioinformatics analyses.
T A O’Mara and JNP co-ordinated the endometrial cancer iCOGS
genotyping, and associated data management. J Dennis, K Michailidou
and J P Tyrer co-ordinated quality control and data cleaning for the iCOGS
datasets, and K Michailidou provided quality control for the SEARCH GWAS
control set. M K Bolla, Q Wang, J P Tyrer and M Shah were responsible for
data management. T A O’Mara and A B Spurdle co-ordinated the ANECS
GWAS genotyping; A M Dunning co-ordinated the SEARCH GWAS
genotyping; I Tomlinson co-ordinated the NSECG GWAS genotyping.
T Cheng, J Attia, E G Holliday, M McEvoy, R J Scott, K Ashton, G Otton,
T Proietto, S Ahmed, C S Healey, M Gorman, L Martin, S Hodgson, P A
Fasching, A Hein, M W Beckmann, A B Ekici, P Hall, K Czene, H Darabi,
J Li, J Dennis, D Annibali, F Amant, E L Goode, S C Dowdy, B L Fridley,
S J Winham, H B Salvesen, T S Njølstad, J Trovik, H M J Werner, E Tham, T Liu,
M Mints J L Hopper, J Peto, A J Swerdlow, B Burwinkel, H Brenner, A Meindl,
H Brauch, A Lindblom, J Chang-Claude, F J Couch, G G Giles, V N Kristensen,
A Cox, The Australian National Endometrial Cancer Study Group, National
Study of Endometrial Cancer Genetics Group, RENDOCAS and the AOCS
Group were involved in the co-ordination and/or extraction of phenotypic
information for contributing studies. All authors provided critical review of
the manuscript.Acknowledgements
The authors thank the many individuals who participated in this study and
the numerous institutions and their staff that supported recruitment,
detailed in full in the Supplementary Text, see section on supplementary
data given at the end of this article. Control data was generated by the
Wellcome Trust Case Control Consortium (WTCCC), and a full list of the
investigators who contributed to the generation of the data is available
from the WTCCC website. We acknowledge use of DNA from the British
1958 Birth Cohort collection. In addition, the results published here are
based partly on data generated by TCGA, established by the NCI and the
National Human Genome Research Institute. The authors also thank the
specimen donors and relevant research groups associated with this project.References
Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M,
Hamann U & Scott RJ 2009 Estrogen receptor polymorphisms and the
risk of endometrial cancer. BJOG: An International Journal of Obstetrics
and Gynaecology 116 1053–1061. (doi:10.1111/j.1471-0528.2009.
02185.x)
Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M,
Hamann U & Scott RJ 2010 Polymorphisms in genes of the steroid
hormone biosynthesis and metabolism pathways and endometrial
cancer risk. Cancer Epidemiology 34 328–337. (doi:10.1016/j.canep.
2010.03.005)
Aulchenko YS, Ripke S, Isaacs A & van Duijn CM 2007 GenABEL:
an R library for genome-wide association analysis. Bioinformatics 23
1294–1296. (doi:10.1093/bioinformatics/btm108)
Bahcall OG 2013 iCOGS collection provides a collaborative model.
Foreword. Nature Genetics 45 343. (doi:10.1038/ng.2592)Published by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research T A O’Mara et al. ESR1 locus fine-mapping for
endometrial cancer
22 :5 860de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ & Altshuler D 2005
Efficiency and power in genetic association studies. Nature Genetics 37
1217–1223. (doi:10.1038/ng1669)
CancerGenomeAtlasResearchNetwork,KandothC, SchultzN,CherniackAD,
Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R et al. 2013
Integrated genomic characterization of endometrial carcinoma. Nature
497 67–73. (doi:10.1038/nature12113)
Carvajal-Carmona LG, O’Mara TA, Painter JN, Lose FA, Dennis J,
Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS et al. 2015
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on
chromosome 5p15 identifies multiple independent variants associated
with endometrial cancer risk. Human Genetics 134 231–245. (doi:10.
1007/s00439-014-1515-4)
Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ,
Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G et al. 2010
ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer
risk: an Ovarian Cancer Association Consortium study. Cancer
Epidemiology, Biomarkers & Prevention 19 245–250. (doi:10.1158/
1055-9965.EPI-09-0729)
Dunning AM, Healey CS, Baynes C,Maia AT, Scollen S, Vega A, Rodriguez R,
Barbosa-Morais NL, Ponder BA, SEARCH et al. 2009 Association of ESR1
gene tagging SNPs with breast cancer risk. Human Molecular Genetics 18
1131–1139. (doi:10.1093/hmg/ddn429)
Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjolander A,
Czene K, Wedren S, Liu ET et al. 2008 ESR1 and EGF genetic variation in
relation to breast cancer risk and survival. Breast Cancer Research 10 R15.
(doi:10.1186/bcr1861)
Einarsdottir K, Darabi H, Czene K, Li Y, Low YL, Li YQ, Bonnard C,Wedren S,
Liu ET, Hall P et al. 2009 Common genetic variability in ESR1 and EGF
in relation to endometrial cancer risk and survival. British Journal of
Cancer 100 1358–1364. (doi:10.1038/sj.bjc.6604984)
Encode Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED,
Gunter C & SnyderM 2012 An integrated encyclopedia of DNA elements
in the human genome. Nature 489 57–74. (doi:10.1038/nature11247)
Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE,
Oei L, Albagha OM, Amin N, Kemp JP et al. 2012 Genome-wide meta-
analysis identifies 56 bone mineral density loci and reveals 14 loci
associated with risk of fracture. Nature Genetics 44 491–501. (doi:10.
1038/ng.2249)
Fan J & Beck KA 2004 A role for the spectrin superfamily member Syne-1
and kinesin II in cytokinesis. Journal of Cell Science 117 619–629.
(doi:10.1242/jcs.00892)
Ferreira T & Marchini J 2011 Modeling interactions with known risk loci-a
Bayesian model averaging approach. Annals of Human Genetics 75 1–9.
(doi:10.1111/j.1469-1809.2010.00618.x)
Fuchsberger C, Abecasis GR & Hinds DA 2015 minimac2: faster
genotype imputation. Bioinformatics 31 782–784. (doi:10.1093/
bioinformatics/btu704)
GhoussainiM, Edwards SL,MichailidouK,Nord S,Cowper-Sal Lari R, Desai K,
Kar S, Hillman KM, Kaufmann S, Glubb DM et al. 2014 Evidence that
breast cancer risk at the 2q35 locus is mediated through IGFBP5
regulation. Nature Communications 4 4999. (doi:10.1038/ncomms5999)
Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S,
Carlebur S, O’Reilly M, Betts JA, Hillman KM et al. 2015 Fine-scale
mapping of the 5q11.2 breast cancer locus reveals at least three
independent risk variants regulating MAP3K1. American Journal of
Human Genetics 96 5–20. (doi:10.1016/j.ajhg.2014.11.009)
Gough LL, Fan J, Chu S, Winnick S & Beck KA 2003 Golgi localization of
Syne-1.Molecular Biology of the Cell 14 2410–2424. (doi:10.1091/mbc.
E02-07-0446)
Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ,
Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquita HB et al.
2012 Comparison of 6q25 breast cancer hits from Asian and European
Genome Wide Association Studies in the Breast Cancer Association
Consortium (BCAC). PLoS ONE 7 e42380. (doi:10.1371/journal.pone.
0042380)http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainHiggins JP & Thompson SG 2002 Quantifying heterogeneity in a meta-
analysis. Statistics in Medicine 21 1539–1558. (doi:10.1002/sim.1186)
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA &
Young RA 2013 Super-enhancers in the control of cell identity and
disease. Cell 155 934–947. (doi:10.1016/j.cell.2013.09.053)
Howie BN, Donnelly P & Marchini J 2009 A flexible and accurate genotype
imputation method for the next generation of genome-wide associ-
ation studies. PLoS Genetics 5 e1000529. (doi:10.1371/journal.pgen.
1000529)
Howie B, Fuchsberger C, Stephens M, Marchini J & Abecasis GR 2012
Fast and accurate genotype imputation in genome-wide association
studies through pre-phasing. Nature Genetics 44 955–959. (doi:10.1038/
ng.2354)
Iwamoto I, Fujino T, Douchi T & Nagata Y 2003 Association of estrogen
receptor a and b3-adrenergic receptor polymorphisms with
endometrial cancer. Obstetrics and Gynecology 102 506–511.
(doi:10.1016/S0029-7844(03)00578-7)
Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones,
and endometrial cancer risk: a synthetic review. Cancer Epidemiology,
Biomarkers & Prevention 11 1531–1543.
Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M & Inoue M
2003 Frequent hypermethylation of MLH1 promoter in normal
endometrium of patients with endometrial cancers. Oncogene 22
2352–2360. (doi:10.1038/sj.onc.1206365)
Key TJ & Pike MC 1988 The dose-effect relationship between ‘unopposed’
oestrogens and endometrial mitotic rate: its central role in explaining
and predicting endometrial cancer risk. British Journal of Cancer 57
205–212. (doi:10.1038/bjc.1988.44)
Kheradpour P & Kellis M 2014 Systematic discovery and characterization of
regulatory motifs in ENCODE TF binding experiments. Nucleic Acids
Research 42 2976–2987. (doi:10.1093/nar/gkt1249)
Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA,
Jordan VC & Bradford AP 2012 DNA profiling analysis of endometrial
and ovarian cell lines reveals misidentification, redundancy and
contamination. Gynecologic Oncology 127 241–248. (doi:10.1016/
j.ygyno.2012.06.017)
Li Y, Willer C, Sanna S & Abecasis G 2009 Genotype imputation.
Annual Review of Genomics and Human Genetics 10 387–406.
(doi:10.1146/annurev.genom.9.081307.164242)
Li Y, Willer CJ, Ding J, Scheet P & Abecasis GR 2010 MaCH: using sequence
and genotype data to estimate haplotypes and unobserved genotypes.
Genetic Epidemiology 34 816–834. (doi:10.1002/gepi.20533)
Li G, Xiang YB, Courtney R, Cheng JR, Huang B, Long JR, Cai H, Zheng W,
ShuXO&CaiQ 2011Association of a single nucleotide polymorphism at
6q25.1,rs2046210, with endometrial cancer risk among Chinese women.
Chinese Journal of Cancer 30 138–143. (doi:10.5732/cjc.010.10516)
Li Q, Seo JH, Stranger B, McKenna A, Pe’er I, Laframboise T, Brown M,
Tyekucheva S & Freedman ML 2013 Integrative eQTL-based analyses
reveal the biology of breast cancer risk loci. Cell 152 633–641.
(doi:10.1016/j.cell.2012.12.034)
Loven J,HokeHA, LinCY, Lau A,OrlandoDA, VakocCR, Bradner JE, Lee TI&
Young RA 2013 Selective inhibition of tumor oncogenes by disruption of
super-enhancers. Cell 153 320–334. (doi:10.1016/j.cell.2013.03.036)
Macintyre G, Bailey J, Haviv I & Kowalczyk A 2010 is-rSNP: a novel
technique for in silico regulatory SNP detection. Bioinformatics 26
i524–i530. (doi:10.1093/bioinformatics/btq378)
Marchini J & Howie B 2010 Genotype imputation for genome-wide
association studies. Nature Reviews. Genetics 11 499–511. (doi:10.1038/
nrg2796)
Marme A, ZimmermannHP, Moldenhauer G, Schorpp-Kistner M,Muller C,
Keberlein O, Giersch A, Kretschmer J, Seib B, Spiess E et al. 2008 Loss of
Drop1 expression already at early tumor stages in a wide range of
human carcinomas. International Journal of Cancer 123 2048–2056.
(doi:10.1002/ijc.23763)
Painter JN, O’Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K,
Tyrer JP, Ahmed S, Ferguson K et al. 2014 Fine-mapping of the HNF1BPublished by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research T A O’Mara et al. ESR1 locus fine-mapping for
endometrial cancer
22 :5 861multicancer locus identifies candidate variants that mediate
endometrial cancer risk. Human Molecular Genetics 24 1478–1492.
(doi:10.1093/hmg/ddu552)
Perry JR,Day F, ElksCE, SulemP,ThompsonDJ, FerreiraT,HeC,ChasmanDI,
Esko T, Thorleifsson G et al. 2014 Parent-of-origin-specific allelic
associations among 106 genomic loci for age at menarche. Nature 514
92–97. (doi:10.1038/nature13545)
Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N & Dahiya R 2002
Polymorphisms of estrogen receptor a gene in endometrial cancer.
Biochemical and Biophysical Research Communications 297 558–564.
(doi:10.1016/S0006-291X(02)02248-9)
Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA,
Van Neste L, Van Criekinge W, van den Bosch S et al. 2007 Comparing
the DNA hypermethylome with gene mutations in human colorectal
cancer. PLoS Genetics 3 1709–1723. (doi:10.1371/journal.pgen.
0030157)
Schwarzer G 2010 Meta: Meta-Analysis with R, package 1.6-1. (available at:
http://CRAN.R-project.org/package=meta)
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N et al. 2006 The consensus coding sequences
of human breast and colorectal cancers. Science 314 268–274.
(doi:10.1126/science.1133427)
Sliwinski T, Sitarek P, Stetkiewicz T, Sobczuk A & Blasiak J 2010
Polymorphism of the ERa and CYP1B1 genes in endometrial cancer in a
Polish subpopulation. Journal of Obstetrics and Gynaecology 36 311–317.
(doi:10.1111/j.1447-0756.2009.01143.x)
Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O’Mara T,
Walker LC, Montgomery SB, Dermitzakis ET, Australian National
Endometrial Cancer Study Group et al. 2011 Genome-wide association
study identifies a common variant associated with risk of endometrial
cancer. Nature Genetics 43 451–454. (doi:10.1038/ng.812)
Sur I, Neumann S & Noegel AA 2014 Nesprin-1 role in DNA damage
response. Nucleus 5 173–191. (doi:10.4161/nucl.29023)http://erc.endocrinology-journals.org q 2015 Society for Endocrinology
DOI: 10.1530/ERC-15-0319 Printed in Great BritainTessemaM,WillinkR,DoK, YuYY, YuW,Machida EO, BrockM,VanNeste L,
Stidley CA, Baylin SB et al. 2008 Promoter methylation of genes in and
around the candidate lung cancer susceptibility locus 6q23-25. Cancer
Research 68 1707–1714. (doi:10.1158/0008-5472.CAN-07-6325)
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, MaranianM, Seal S,
Ghoussaini M, Hines S, Healey CS et al. 2010 Genome-wide association
study identifies five new breast cancer susceptibility loci. Nature
Genetics 42 504–507. (doi:10.1038/ng.586)
Ward LD & Kellis M 2012 HaploReg: a resource for exploring chromatin
states, conservation, and regulatory motif alterations within sets of
genetically linked variants. Nucleic Acids Research 40 D930–D934.
(doi:10.1093/nar/gkr917)
Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC,
Kindmark A, Landegren U, Fermer ML, Stiger F et al. 2008
Estrogen receptor a gene polymorphism and endometrial cancer
risk – a case–control study. BMC Cancer 8 322. (doi:10.1186/1471-2407-
8-322)
Weiderpass E, Persson I, Melhus H,Wedren S, Kindmark A & Baron JA 2000
Estrogen receptor a gene polymorphisms and endometrial cancer risk.
Carcinogenesis 21 623–627. (doi:10.1093/carcin/21.4.623)
WhyteWA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, KageyMH, Rahl PB,
Lee TI & Young RA 2013 Master transcription factors and mediator
establish super-enhancers at key cell identity genes. Cell 153 307–319.
(doi:10.1016/j.cell.2013.03.035)
Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG,Weissberg PL,
Ellis JA & Shanahan CM 2001 Nesprins: a novel family of spectrin-
repeat-containing proteins that localize to the nuclear membrane in
multiple tissues. Journal of Cell Science 114 4485–4498.
ZhengW,Long J,GaoYT, LiC,ZhengY,XiangYB,WenW,LevyS,DemingSL,
Haines JL et al. 2009 Genome-wide association study identifies a new
breast cancer susceptibility locus at 6q25.1. Nature Genetics 41 324–328.
(doi:10.1038/ng.318)Received in final form 31 July 2015
Accepted 5 August 2015Published by Bioscientifica Ltd.
